YHLO produced COVID-19 Rapid Test Authorized by Japanese PMDA
On February 10th, 2022, YHLO produced COVID-19 Rapid Antigen Test Kit was authorized by Japanese PMDA (Pharmaceuticals and Medical Devices Agency), which is supplied to YHLO’s Japanese marketing authorization holder, MBL (MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.). With the Japanese PMDA certificate, the product will be available for sale in Japan, which can be used for professional use and self-testing.
Attachments:
Previous
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
